DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in VEMLIDY is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
Generic Entry Opportunity Date for 208464
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 25MG BASE|
|Approval Date:||Nov 10, 2016||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Nov 5, 2020|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||Nov 11, 2019|
|Regulatory Exclusivity Use:||NEW PRODUCT|
|Patent:||➤ Try a Free Trial||Patent Expiration:||May 7, 2022||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription